Rani Therapeutics Holdings, Inc.

How big is Rani Therapeutics Holdings, Inc.?

As of Jun 18, Rani Therapeutics Holdings, Inc. has a market capitalization of 29.57 million and reported net sales of 1.20 million with a net profit of -54.54 million over the last four quarters. The company has shareholder's funds of 1.99 million and total assets of 36.63 million as of Dec 24.

Market Cap: As of Jun 18, Rani Therapeutics Holdings, Inc. has a market capitalization of 29.57 million, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Rani Therapeutics reported net sales of 1.20 million and a net profit of -54.54 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1.99 million and total assets of 36.63 million.

What does Rani Therapeutics Holdings, Inc. do?

Rani Therapeutics Holdings, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 million and a net loss of $13 million as of March 2025. The company has a market cap of $29.57 million and does not pay dividends.

Overview: <BR>Rani Therapeutics Holdings, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -13 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 29.57 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.93 <BR>Return on Equity: 1,663.25% <BR>Price to Book: -9.68<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Should I buy, sell or hold Rani Therapeutics Holdings, Inc.?

Is Rani Therapeutics Holdings, Inc. overvalued or undervalued?

As of March 31, 2025, Rani Therapeutics Holdings, Inc. is classified as risky and overvalued due to negative financial metrics, including a Price to Book Value of -10.54 and a year-to-date return of -64.23%, significantly underperforming the S&P 500.

As of 31 March 2025, the valuation grade for Rani Therapeutics Holdings, Inc. has moved from does not qualify to risky. The company is currently considered overvalued given its negative financial metrics and significant losses. Key ratios include a Price to Book Value of -10.54, an EV to EBIT of -0.80, and an EV to EBITDA of -0.82, all indicating severe financial distress.<BR><BR>In comparison to peers, Rani Therapeutics has a valuation of risky with a P/E ratio that is not applicable due to losses, while Avrobio, Inc. and Spero Therapeutics, Inc. are also classified as does not qualify and risky, respectively, with P/E ratios of -6.6206 and -2.3598. The company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -64.23% compared to the index's 2.44%, reinforcing the notion that Rani Therapeutics is overvalued in its current state.

Is Rani Therapeutics Holdings, Inc. technically bullish or bearish?

As of July 1, 2025, Rani Therapeutics Holdings, Inc. has a mildly bearish trend, with mixed indicators showing mild bullishness in MACD and KST but bearish signals in moving averages and Bollinger Bands, while the stock has underperformed the S&P 500 significantly, with a year-to-date return of -64.85%.

As of 1 July 2025, the technical trend for Rani Therapeutics Holdings, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a mix of indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI shows a bullish signal on the monthly but no signal on the weekly. However, moving averages are bearish on the daily, and Bollinger Bands are bearish on both weekly and monthly time frames. KST is mildly bullish weekly but bearish monthly, and Dow Theory indicates a mildly bullish stance monthly with no trend weekly. <BR><BR>In terms of performance, the stock has significantly underperformed compared to the S&P 500 across all periods, with a year-to-date return of -64.85% versus the S&P 500's 12.22%, and a one-year return of -79.06% compared to 17.14% for the index.